Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Immunotherapy in myeloma: current strategies and future perspectives

Ajai Chari, Niels van de Donk and Saad Usmani • 12 Sep 2019
IMW 2019
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Elotuzumab Lenalidomide Pomalidomide
ASPIRE DREAMM-2 ENDEAVOUR

Saad Usmani, MD, FACP, Levine Cancer Institute, Charlotte, NC, is joined by Ajai Chari, MD, PhD, Mount Sinai Medical Center, New York, NY and Niels van de Donk, MD, PhD, VU University Medical Center, Amsterdam, at the International Myeloma Workshop (IMW) 2019, held in Boston, MA. The speakers discuss different modalities of immunotherapy developed in myeloma, including monoclonal antibodies, myeloma microenvironment and immune signalling.

More from Ajai Chari

2:34
The effect of dose reduction of talquetamab in patients with R/R MM: results from MonumenTAL-1
Ajai Chari • 10 Dec 2023
3:04
MonumenTAL-1 update: talquetamab in R/R multiple myeloma
Ajai Chari • 5 Dec 2022
1:53
Infections following anti-BCMA bispecific antibodies for multiple myeloma
Ajai Chari • 5 Dec 2022
1:17
An update on GRIFFIN: D-RVd in patients with newly diagnosed multiple myeloma
Ajai Chari • 5 Dec 2022

More from Niels van de Donk

4:33
Cilta-cel elicits deep and durable responses in patients with multiple myeloma with early relapse
Niels van de Donk • 13 Dec 2021
2:42
Iberdomide plus dexamethasone for heavily pretreated multiple myeloma
Niels van de Donk • 13 Dec 2021
3:03
The future of CAR-T therapy for multiple myeloma
Niels van de Donk • 13 Dec 2021
1:45
Mechanisms of action of CD38 antibodies in myeloma
Niels van de Donk • 13 Dec 2021

More from Saad Usmani

1:14
Clinical benefit of teclistamab vs real-world physician’s choice for R/R multiple myeloma
Saad Usmani • 8 Sep 2023
1:53
MajesTEC‐1 update: rates of infection in patients with myeloma receiving teclistamab
Saad Usmani • 8 Sep 2023
1:43
High-risk multiple myeloma: addressing challenges and unmet needs
Saad Usmani • 8 Sep 2023
2:05
Exciting ongoing trials in frontline transplant-eligible patients with multiple myeloma
Saad Usmani • 25 Aug 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals